
Unlocking longevity through in-situ Hematopoietic Stem Cell Rejuvenation using combined modulation of aging-disrupted pathways identified by publicly available and proprietary single-cell datasets from young and old human populations. Stem-cell exhaustion is a key hallmark of aging, contributing to impaired tissue repair, immune dysfunction, and systemic frailty. In this project, we took a novel approach to this challenge—rather than replacing aged blood-forming stem cells (HSCs) through transplantation, the project seeks to rejuvenate the body’s own stem cells in situ. We have analysed nearly 850,000 single-cell transcriptomes from healthy donors aged 23 to 91 from publically available and proprietary datasets, generating a high-resolution atlas of hematopoietic aging. The data reveal consistent age-related molecular signatures: younger HSCs show elevated expression of DNA repair and mitochondrial genes, while older cells exhibit ferroptosis drivers, inflammatory signaling (notably TNF and IL-17), and upregulation of CCR9 and long non-coding RNAs. These findings were confirmed in both circulating and bone marrow-derived HSCs, reinforcing their potential as biomarkers and intervention targets. In conclusion, we have identified a list of target genes, which can be used as a intervention for hematopoietic stem cell rejuvenation studies. The key insight is that we are targeting multiple aging mechanisms simultaneously - transcriptional stress responses, epigenetic regulation, and protein homeostasis. Classic damage repair thinking applied to the molecular level. This multi-pronged approach could achieve the robust rejuvenation that single interventions miss.
Unlocking longevity through in-situ Hematopoietic Stem Cell Rejuvenation using combined modulation of aging-disrupted pathways identified by publicly available and proprietary single-cell datasets from young and old human populations.
Stem-cell exhaustion is a key hallmark of aging, contributing to impaired tissue repair, immune dysfunction, and systemic frailty. In this project, we took a novel approach to this challenge—rather than replacing aged blood-forming stem cells (HSCs) through transplantation, the project seeks to rejuvenate the body’s own stem cells in situ. We have analysed nearly 850,000 single-cell transcriptomes from healthy donors aged 23 to 91 from publically available and proprietary datasets, generating a high-resolution atlas of hematopoietic aging. The data reveal consistent age-related molecular signatures: younger HSCs show elevated expression of DNA repair and mitochondrial genes, while older cells exhibit ferroptosis drivers, inflammatory signaling (notably TNF and IL-17), and upregulation of CCR9 and long non-coding RNAs. These findings were confirmed in both circulating and bone marrow-derived HSCs, reinforcing their potential as biomarkers and intervention targets. In conclusion, we have identified a list of target genes, which can be used as a intervention for hematopoietic stem cell rejuvenation studies. The key insight is that we are targeting multiple aging mechanisms simultaneously - transcriptional stress responses, epigenetic regulation, and protein homeostasis. Classic damage repair thinking applied to the molecular level. This multi-pronged approach could achieve the robust rejuvenation that single interventions miss.
Therapeutic Relevance
The proposed mechanism is scientifically plausible and well-grounded. HSC aging is a biologically validated driver of immune decline, anemia, and hematologic malignancies. The project targets well-characterized aging pathways (DNA repair, mitochondrial dysfunction, epigenetic drift, inflammatory signaling) identified through analysis of ~850,000 single-cell transcriptomes spanning ages 23–91, lending strong biological credibility. The multi-modal approach targeting intrinsic HSC dysfunction (NR4A1/2, JUNB, FOS, UHRF1, MPO, XIST) and extrinsic niche factors addresses a genuine unmet medical need. Key targets like CD38 (NAD+ preservation) and RhoA (chromatin accessibility) have existing literature support. However, the score is not a 5 because all evidence remains computational/bioinformatic — no functional validation has been performed to confirm that modulating these specific targets actually rejuvenates HSCs. The AubrAI-generated hypothesis, while comprehensive, is speculative and untested. The multi-target approach, while ambitious, also introduces complexity risk regarding which combinations are truly necessary and sufficient.
Therapeutic Optionality
The concept demonstrates strong therapeutic optionality. HSC rejuvenation could address multiple therapeutic areas: age-related immune decline (immunosenescence), anemia, myelodysplastic syndromes, leukemia prevention, chronic inflammation, and broader regenerative medicine applications. The multi-modal intervention framework (mRNA, siRNA, small molecules, CRISPR, gene therapy) provides flexibility in modality selection. Several targets (e.g., CD38 inhibition, RhoA inhibition) have potential applications beyond HSCs. The platform approach — using scRNA-seq + AI/ML to identify aging targets — could theoretically be extended to other stem cell populations (e.g., mesenchymal, neural, intestinal stem cells). The concept also spans drug repurposing (cromolyn sodium for TPSB2/TPSAB1) and novel drug discovery. A score of 5 is not warranted because the optionality remains theoretical at this stage, and the core focus is narrowly on HSCs without demonstrated cross-tissue applicability.
Intellectual Property
The IP position is moderate with both strengths and risks. Strengths: The specific combination of targets identified through proprietary computational analysis (multi-modal HSC rejuvenation cocktail) could be patentable as a novel therapeutic combination. The use of proprietary datasets alongside public data, and the specific AI/ML-derived intervention protocol (temporal phasing, specific target combinations), may provide a basis for composition-of-matter or method-of-treatment claims. No patents have been filed yet, which is appropriate at TRL 1 but also means the IP is currently unprotected. Risks: Many individual targets (CD38, RhoA, NR4A family, rapamycin, senolytics) are well-known in the aging/hematopoiesis literature, creating significant prior art concerns. Several proposed small molecules (Fasudil, rapamycin, cromolyn sodium) are existing drugs, limiting composition-of-matter claims. The scRNA-seq datasets used are partially publicly available, and the specific gene targets (once disclosed) could be independently identified by competitors using similar bioinformatic approaches. The document explicitly withholds gene names, suggesting awareness of IP vulnerability. Competition in the HSC rejuvenation space is growing. Overall, the novelty likely resides in the specific combination and temporal protocol rather than individual targets.